A Phase 1/2a Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493, a Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor, in Subjects With Advanced Hepatocellular Carcinoma
Phase of Trial: Phase I
Latest Information Update: 24 Jul 2017
At a glance
- Drugs Erdafitinib (Primary)
- Indications Liver cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Janssen Research & Development
- 16 Jun 2017 Planned primary completion date changed from 20 Aug 2017 to 31 May 2019.
- 20 Jan 2017 Planned End Date changed from 1 Jun 2019 to 1 May 2019.
- 25 Nov 2016 Planned number of patients changed from 52 to 58.